Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for prevention and treatment of camrelizumab-induced RCCEP in advanced NSCLC
ChiCTR2400091929Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thalidomide in non-small cell lung cancer (NSCLC) and reactive skin capillary hyperplasia (RSCH) (2 cohorts), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Incidence of RCCEP of any grade and Recovery rate of RCCEP. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)reactive skin capillary hyperplasia (RSCH)
Beyond the preview
Go deeper on ChiCTR2400091929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091929.